Michael W. Meshad
About
In The Last Decade
Michael W. Meshad
9 papers receiving 138 citations
Peers
Comparison fields: 5 of 40
- Surgery 72
- Oncology 68
- Otorhinolaryngology 41
- Pulmonary and Respiratory Medicine 25
- Molecular Biology 24
Countries citing papers authored by Michael W. Meshad
This map shows the geographic impact of Michael W. Meshad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Meshad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Meshad more than expected).
Fields of papers citing papers by Michael W. Meshad
This network shows the impact of papers produced by Michael W. Meshad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Meshad. The network helps show where Michael W. Meshad may publish in the future.
Co-authorship network of co-authors of Michael W. Meshad
This figure shows the co-authorship network connecting the top 25 collaborators of Michael W. Meshad. A scholar is included among the top collaborators of Michael W. Meshad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael W. Meshad. Michael W. Meshad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 3 | |
| 3 | 0 | |
| 4 | 7 | |
| 5 | 16 | |
| 6 | Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience. | 12 |
| 7 | 30 | |
| 8 | Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy. | 15 |
| 9 | Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM). | 60 |
| 10 | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.